Showing results (1-10 of 576) with videos related to

Sort By:
Pageof 58
Current Treatment Options in Oncology|May 4, 2012
Targeted therapy for gastric cancerElizabeth C Smyth, David Cunningham
World Journal of Gastrointestinal Oncology|June 18, 2014
Operable gastro-oesophageal junctional adenocarcinoma: Where to next?Elizabeth C Smyth, David Cunningham
Oncotargets and Therapy|August 16, 2016
Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinomaMichael Davidson, Elizabeth C Smyth, David Cunningham
Current Treatment Options in Oncology|April 2, 2016
Esophagogastric Adenocarcinoma: Is More Chemotherapy Better?Elisa Fontana, Elizabeth C Smyth, David Cunningham
Oncotargets and Therapy|June 25, 2014
Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitorsElizabeth C Smyth, Francesco Sclafani, David Cunningham
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 19, 2014
Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?Sing Yu Moorcraft, Elizabeth C Smyth, David Cunningham
Therapeutic Advances in Gastroenterology|September 5, 2013
The role of personalized medicine in metastatic colorectal cancer: an evolving landscapeSing Yu Moorcraft, Elizabeth C Smyth, David Cunningham
Journal of Surgical Oncology|January 6, 2015
A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomyKyriakos Neofytou, Alexandros Giakoustidis, Elizabeth C Smyth, et al.
Medical Oncology (Northwood, London, England)|September 15, 2014
Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factorKyriakos Neofytou, Elizabeth C Smyth, Alexandros Giakoustidis, et al.
Clinical Colorectal Cancer|January 10, 2016
Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?Elizabeth C Smyth, Noelia Tarazona, Clare Peckitt, et al.
Pageof 58